HAVCR2 and glioblastoma: We will discuss studies describing TIM-3 as a potential biomarker for glioblastoma prognosis, its expression on several immune cell subtypes, and potential TIM-3 based therapeutic avenues that may offer greater clinical success than current immunotherapy-based agents.